DailyIQ
DailyIQ
Last updatedUpdating…

LEGN·Legend Biotech Corporation

$23.64
+1.10 (+4.88%)
High
$23.64
Open
$23.09
Market Cap
4.41B
52W High
$37.50
Low
$22.23
P. Close
$23.64
P/E
-
52W Low
$16.24
Fwd P/E
21.90
DailyIQ Est.
$49.39
Inst. Own.
6.4%
Short Interest
7.43%
Days to Cover
6.7
Technical Score (1D)
7
BEARISH
News Sentiment
57
BULLISH
On Nov 4, Legend Biotech announced that multiple abstracts had been accepted for the 2026 American Society of Hematology meeting, including new analyses from the CARTITUDE‑4 study and data from the first‑in‑human trial of LB2501. The presentations will cover clinical outcomes for CARVYKTI in multiple myeloma and showcase next‑generation cell therapy programs. The announcement highlighted ongoing progress in the company’s CAR‑T pipeline and its commitment to advancing treatment options. The new CARTITUDE‑4 subgroup analyses were reported to provide insights into durable outcomes. The first‑in‑human data on LB2501, a dual‑targeting CD19/CD20 CAR‑T therapy, will also be presented.
LOW TARGET
$24 +1.5%
2 analysts
MEAN TARGET
$46 +93.0%
12 analysts
HIGH TARGET
$68 +187.7%
10 analysts
PRICE RANGE
$24.00 - $68.00
SB / B / H / S / SS
5/11/6/1/1
DAILYIQ EST.
$49.39 (+108.9%)
Bought (1Y)
0 shares
$0
Sold (1Y)
32,800 shares
$309K
Sanders Corazon (Corsee) D.-
Sell27,370 shares2026-09-29
Sanders Corazon (Corsee) D.-
Award/Grant20,986 shares2026-09-24
Ji Darren Xiaohui-
Award/Grant28,330 shares2026-09-24
Casey Patrick John-
Award/Grant20,986 shares2026-09-24
Mao Li-
Award/Grant20,986 shares2026-09-24
100/ 100
Strong bullish
Overall: Bullish
✓Analyst target above current price

EPS

EstBeatMiss
$-0.25$-0.18$-0.11$-0.04$0.03Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.00 - -
Q3'25$-0.18$-0.22-18.9%

Revenue

EstBeatMiss
$258M$289M$321M$352M$383MQ3'25Q3'26
QtrEstActual+/−
Q3'26$369M - -
Q3'25 - $272M -

Market Data

LEGN Stock Snapshot

BEARISH7/100
$23.64+$1.10 (4.9%)
Market cap
4.41B
Day range
$22.23 – $23.64
News sentiment
57/100 · Neutral
Analyst target
$45.62 (+93.0%)
Consensus
Buy · 24 analysts
52-week range+45.6% off low · -37.0% from high
$16.24$37.50
Price $23.64 DailyIQ Est. $49.39

The signals on LEGN lean bearish, and the range position backs that up. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Behaviour On Record

What LEGN's own history says about today's numbers

Realized volatility (21d)
54.0% 58th pct
Below its peak
-70.1%
vs 200-day average
+3.4%
Up days (1y)
43%

Legend Biotech Corporation is currently running 54.0% annualised volatility over the last 21 sessions. Measured against LEGN's own 6 years of daily returns rather than a market-wide average, that is the 58th percentile — close to its own typical level, against a typical reading of 49.6%.

LEGN is trading -70.1% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -43.8%, and the deepest was -53.6% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits +3.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 62nd percentile — a somewhat wider gap than its own norm. Over the past year LEGN closed higher on 43% of sessions, and it is currently 3 sessions into a rising streak.

On November specifically: over 6 years of records, LEGN finished the month higher 2 of 6 times, with a median return of -3.7% and an average of -1.3%. Its strongest month historically has been June at +15.3% on average, its weakest December at -9.1%.

Overnight risk is measurable too: LEGN has opened more than 2% away from the prior close in 199 of 1,612 sessions (12.3% of the time), with the largest gaps running +7.4% and -6.5%.

All figures computed from 1,613 daily closes between 2020-06-08 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against LEGN's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of LEGN's sector?

Legend Biotech Corporation sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, LEGN ranks 6th of 15 tracked industries, weakening.

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100
Industry rank
#6 of 15

Options Market

What is the options market pricing for LEGN?

CallsPuts

For Legend Biotech Corporation's nearest expiry (2026-11-20, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.15), with at-the-money implied volatility around 65.0%. The options market is pricing roughly a ±17.7% move by that expiry — a range of about $19.32–$27.64.

Put/call ratio (2026-11-20)
0.15
ATM implied volatility
65.0%
Total open interest
4,756
Expected move by 2026-11-20
±17.7% ($19.32–$27.64)

Analyst Consensus Estimates

What do analysts expect LEGN to earn?

Analysts expect Legend Biotech Corporation to earn -$0.01 per share in the fiscal year ending Dec 2026 and $2.87 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026$0.01$0.01 to $0.011$360M9
Dec 2026$0.09$0.09 to $0.091$382M9
Mar 2027$0.23$0.13 to $0.284~$352M-
Jun 2027$0.30$0.21 to $0.364~$459M-
Sep 2027$0.35$0.31 to $0.444~$535M-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$0.01-$0.01 to -$0.011$1.44B10
Dec 2027$0.68$0.32 to $1.052$1.77B10
Dec 2028$2.39$2.16 to $2.664--
Dec 2029$2.87$2.16 to $3.582--

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on LEGN?

Barclays most recently reiterated its rating on Legend Biotech Corporation to Overweight on Oct 13, 2026 with a price target of $68 (from $74). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
Barclays: Overweight
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 13, 2026BarclaysMaintainedOverweight$74 → $68
Oct 9, 2026JP MorganMaintainedNeutral$35 → $33
Oct 8, 2026RBC CapitalMaintainedOutperform$58 → $56
Sep 30, 2026HC Wainwright & Co.ReiteratedBuy$65
Sep 11, 2026BarclaysMaintainedOverweight$78 → $74
Sep 4, 2026HC Wainwright & Co.ReiteratedBuy$65
Aug 12, 2026Morgan StanleyMaintainedOverweight$48 → $49
Aug 12, 2026TD CowenMaintainedHold$29 → $24
Aug 12, 2026OppenheimerDowngradeOutperform → Perform$75 → $40
Aug 12, 2026RBC CapitalMaintainedOutperform$59 → $58
Aug 12, 2026BarclaysMaintainedOverweight$80 → $78
Jul 28, 2026HC Wainwright & Co.ReiteratedBuy$65

Corporate Stakes

Which companies own a stake in LEGN?

0.44%held by JNJ

Johnson & Johnson reports a stake in Legend Biotech Corporation on SEC Form 13F: 814.6K shares, about 0.44% of the company, worth $16.2M at the end of Q3 2026. At today's price that stake is worth $19.3M, about 0.00% of JNJ's own market value.

Holder
JNJ
Shares held
814.6K
Stake
0.44%
Value
$16.2M
HolderLast quarterShares% of LEGNValue at filingValue nowChange
Johnson & Johnson JNJUnchanged814.6K0.44%$16.2M$19.3M+18.9%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

News & sentiment

What is the news saying about LEGN?

LEGN rose 25.2% over the month to Nov 6. News tone held between 0 and 95 from Oct 8 to Oct 20, then jumped to 75 on Oct 27.

Daily close and news tone, Oct 6 to Nov 6
$18$20$23Oct 6Oct 7Oct 8: tone 16Oct 9Oct 12Oct 13Oct 14Oct 15: tone 95Oct 16Oct 19Oct 20: tone 0Oct 21Oct 22Oct 23Oct 26Oct 27: tone 75Oct 28: tone 67Oct 29: tone 99Oct 30Nov 2: tone 32Nov 3Nov 4: tone 58Nov 5Nov 6Oct 6News toneNov 6123
  1. Oct 14 +6.4%
  2. Oct 16 -6.2%
  3. Nov 4 +6.1%same day: Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

Technical analysis

How strong is LEGN's momentum right now?

On the daily chart LEGN ranks at the 7th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling LEGN?

45 of the 85 tracked managers added to LEGN in their latest 13F and 34 trimmed. Together they own 6.0% of the company, worth $318.9M. State Street and Capital International Investors alone hold 1.6%.

45adding34trimming6unchanged
Largest holders by stake, latest 13FBar = share of LEGN
  1. $43.3M positionAdded 0.0% last quarter
  2. $41.0M positionAdded 119.3% last quarter
  3. $33.5M positionNew position last quarter
  4. $21.9M positionAdded 86.8% last quarter
  5. $19.1M positionAdded 222.1% last quarter
  6. $16.6M positionTrimmed 0.0% last quarter
  7. $14.5M positionAdded 64.6% last quarter
  8. $9.8M positionTrimmed 61.2% last quarter
  9. $8.9M positionAdded 297.0K shares last quarter
  10. $7.3M positionAdded 7.2% last quarter
Full holdings history

Discover more

How has LEGN done against its peers?

Over the six months to Nov 6, LEGN returned −18.7%. Of the 15 related stocks and ETFs, 14 did better, led by MRNA at +436.2%.

Change since May 6, through Nov 6
−200%0%+200%+400%+600%May 6JunJulAugSepOctNov 6MRNA +436.2%LEGN −18.7%INSM −19.9%